Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$5.49 USD
+0.19 (3.58%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $5.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.49 USD
+0.19 (3.58%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $5.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Zacks.com featured highlights include: Genesco, Hertz Global, Suburban Propane, and Cytek
by Zacks Equity Research
Zacks.com featured highlights include: Genesco, Hertz Global, Suburban Propane, and Cytek.
4 Top Stocks for Higher Returns on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Genesco (GCO), Hertz (HTZ), Suburban (SPH) and Cytek (CTKB).
Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.